Vigilare Wealth Management reduced its position in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 3.1% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 11,347 shares of the company’s stock after selling 362 shares during the period. Johnson & Johnson makes up about 1.0% of Vigilare Wealth Management’s investment portfolio, making the stock its 15th largest position. Vigilare Wealth Management’s holdings in Johnson & Johnson were worth $1,759,000 at the end of the most recent quarter.
Other hedge funds have also recently bought and sold shares of the company. Moneta Group Investment Advisors LLC increased its stake in Johnson & Johnson by 90,144.4% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock worth $9,607,414,000 after purchasing an additional 54,326,454 shares in the last quarter. Norges Bank purchased a new position in Johnson & Johnson in the 4th quarter worth about $4,609,399,000. Morgan Stanley increased its stake in Johnson & Johnson by 12.0% in the 4th quarter. Morgan Stanley now owns 42,224,521 shares of the company’s stock worth $7,458,962,000 after purchasing an additional 4,521,062 shares in the last quarter. Nordwand Advisors LLC purchased a new position in Johnson & Johnson in the 4th quarter worth about $785,273,000. Finally, Price T Rowe Associates Inc. MD grew its stake in Johnson & Johnson by 15.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 29,277,774 shares of the company’s stock valued at $5,171,919,000 after acquiring an additional 3,849,148 shares in the last quarter. 67.57% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
Several equities analysts have weighed in on the company. StockNews.com assumed coverage on Johnson & Johnson in a research note on Thursday, May 18th. They set a “strong-buy” rating on the stock. UBS Group assumed coverage on Johnson & Johnson in a research note on Tuesday, March 28th. They set a “neutral” rating and a $164.00 target price on the stock. Citigroup assumed coverage on Johnson & Johnson in a research note on Tuesday, May 30th. They set a “buy” rating and a $185.00 target price on the stock. TheStreet cut Johnson & Johnson from a “b” rating to a “c+” rating in a research note on Friday, May 19th. Finally, Atlantic Securities reduced their price target on Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating for the company in a report on Wednesday, April 19th. Seven analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $171.57.
Johnson & Johnson Stock Down 1.4 %
JNJ opened at $163.26 on Tuesday. The business has a 50 day moving average price of $160.78 and a 200 day moving average price of $162.82. Johnson & Johnson has a twelve month low of $150.11 and a twelve month high of $181.04. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.85 and a current ratio of 1.07. The firm has a market cap of $424.27 billion, a P/E ratio of 34.15, a price-to-earnings-growth ratio of 2.83 and a beta of 0.55.
Johnson & Johnson (NYSE:JNJ – Free Report) last issued its quarterly earnings results on Tuesday, April 18th. The company reported $2.68 EPS for the quarter, topping the consensus estimate of $2.51 by $0.17. The company had revenue of $24.75 billion for the quarter, compared to the consensus estimate of $23.61 billion. Johnson & Johnson had a return on equity of 36.13% and a net margin of 13.22%. The company’s revenue for the quarter was up 5.6% on a year-over-year basis. During the same period in the previous year, the business posted $2.67 EPS. Research analysts forecast that Johnson & Johnson will post 10.66 EPS for the current year.
Johnson & Johnson Increases Dividend
The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 6th. Shareholders of record on Tuesday, May 23rd were given a $1.19 dividend. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.13. This represents a $4.76 annualized dividend and a yield of 2.92%. The ex-dividend date of this dividend was Monday, May 22nd. Johnson & Johnson’s payout ratio is currently 99.58%.
Insiders Place Their Bets
In other news, EVP Kathryn E. Wengel sold 12,465 shares of the business’s stock in a transaction that occurred on Monday, June 12th. The stock was sold at an average price of $160.00, for a total transaction of $1,994,400.00. Following the sale, the executive vice president now directly owns 65,934 shares in the company, valued at $10,549,440. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 0.20% of the company’s stock.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Featured Stories
Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.